Transverse myelitis pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 2: Line 2:
{{Transverse myelitis}}
{{Transverse myelitis}}


{{CMG}}; {{AE}} {{MMJ}}
{{CMG}}; {{AE}} {{MMJ}}{{sali}}
==Overview==
==Overview==



Revision as of 04:19, 6 May 2020

Transverse myelitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Transverse myelitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Transverse myelitis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Transverse myelitis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Transverse myelitis pathophysiology

CDC on Transverse myelitis pathophysiology

Transverse myelitis pathophysiology in the news

Blogs on Transverse myelitis pathophysiology

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Transverse myelitis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2] Syed Musadiq Ali M.B.B.S.[3]

Overview

  • In the pathogenesis of transverse myelitis, a variety of immunological mechanisms may cause pathological substrate and dysfunction of neural cells within the spinal cord.
  • Other histopathological findings of transverse myelitis include:
    • Infiltration of CD4+ and CD8+ T-lymphocytes
    • Typically preservation of the subpial parenchyma suggesting ischemia as the ultimate cause of the cord lesions in transverse myelitis

Conditions that may cause transverse myelitis include:

Infections can cause transverse myelitis through two main mechanisms:

  1. Direct tissue damage
  2. Immune-mediated infection-triggered tissue damage which may be due to: Molecular mimicry or superantigen effect

A non-microbial related immune dysfunction by the presence of autoantibodies has been also proposed in the immunopathogenesis of transverse myelitis.

In the spinal fluid of patients with transverse myelitis, Interleukin 6 (IL-6) levels were also markedly elevated.


Pathophysiology

Physiology

Pathogenesis

  • In the pathogenesis of transverse myelitis, a variety of immunological mechanisms may cause pathological substrate and dysfunction of neural cells within the spinal cord.[3]
  • Other histopathological findings of transverse myelitis include:[1][5]
    • Infiltration of CD4+ and CD8+ T-lymphocytes
    • Typically preservation of the subpial parenchyma suggesting ischemia as the ultimate cause of the cord lesions in transverse myelitis

Conditions that may cause transverse myelitis include:

Infections can cause transverse myelitis through two main mechanisms:[1][14][16]

  1. Direct tissue damage
  2. Immune-mediated infection-triggered tissue damage which may be due to: Molecular mimicry or superantigen effect

A non-microbial related immune dysfunction by the presence of autoantibodies has been also proposed in the immunopathogenesis of transverse myelitis.[1][17][18][19]

In the spinal fluid of patients with transverse myelitis, Interleukin 6 (IL-6) levels were also markedly elevated.[1][8][20]

Associated Conditions

Conditions associated with transverse myelitis include:[21][22][1][3][23]

Microscopic Pathology

Findings on microscopic histopathological analysis of transverse myelitis include:[24][25]

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 Awad A, Stüve O (2011). "Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices". Curr Neuropharmacol. 9 (3): 417–28. doi:10.2174/157015911796557948. PMC 3151596. PMID 22379456.
  2. Tavasoli A, Tabrizi A (2018). "Acute Transverse Myelitis in Children, Literature Review". Iran J Child Neurol. 12 (2): 7–16. PMC 5904733. PMID 29696041.
  3. 3.0 3.1 Kerr DA, Ayetey H (2002). "Immunopathogenesis of acute transverse myelitis". Curr Opin Neurol. 15 (3): 339–47. doi:10.1097/00019052-200206000-00019. PMID 12045735.
  4. Meyer P, Leboucq N, Molinari N, Roubertie A, Carneiro M, Walther-Louvier U; et al. (2014). "Partial acute transverse myelitis is a predictor of multiple sclerosis in children". Mult Scler. 20 (11): 1485–93. doi:10.1177/1352458514526943. PMID 24619933.
  5. Moulignier A, Lescure FX, Savatovsky J, Campa P (2014). "CD8 transverse myelitis in a patient with HIV-1 infection". BMJ Case Rep. 2014. doi:10.1136/bcr-2013-201073. PMC 3918629. PMID 24503658.
  6. Jeffery DR, Mandler RN, Davis LE (1993). "Transverse myelitis. Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events". Arch Neurol. 50 (5): 532–5. doi:10.1001/archneur.1993.00540050074019. PMID 8489410.
  7. Christensen PB, Wermuth L, Hinge HH, Bømers K (1990). "Clinical course and long-term prognosis of acute transverse myelopathy". Acta Neurol Scand. 81 (5): 431–5. doi:10.1111/j.1600-0404.1990.tb00990.x. PMID 2375246.
  8. 8.0 8.1 Krishnan C, Kaplin AI, Deshpande DM, Pardo CA, Kerr DA (2004). "Transverse Myelitis: pathogenesis, diagnosis and treatment". Front Biosci. 9: 1483–99. doi:10.2741/1351. PMID 14977560.
  9. PAINE RS, BYERS RK (1953). "Transverse myelopathy in childhood". AMA Am J Dis Child. 85 (2): 151–63. doi:10.1001/archpedi.1953.02050070160004. PMID 13007166.
  10. Ropper AH, Poskanzer DC (1978). "The prognosis of acute and subacute transverse myelopathy based on early signs and symptoms". Ann Neurol. 4 (1): 51–9. doi:10.1002/ana.410040110. PMID 697326.
  11. Knebusch M, Strassburg HM, Reiners K (1998). "Acute transverse myelitis in childhood: nine cases and review of the literature". Dev Med Child Neurol. 40 (9): 631–9. doi:10.1111/j.1469-8749.1998.tb15430.x. PMID 9766742.
  12. ALTROCCHI PH (1963). "ACUTE TRANSVERSE MYELOPATHY". Arch Neurol. 9: 111–9. doi:10.1001/archneur.1963.00460080021002. PMID 14048158.
  13. Lerer RJ, Kalavsky SM (1973). "Central nervous system disease associated with Mycoplasma pneumoniae infection: report of five cases and review of the literature". Pediatrics. 52 (5): 658–68. PMID 4598176.
  14. 14.0 14.1 Salgado CD, Weisse ME (2000). "Transverse myelitis associated with probable cat-scratch disease in a previously healthy pediatric patient". Clin Infect Dis. 31 (2): 609–11. doi:10.1086/313986. PMID 10987731.
  15. Agmon-Levin N, Kivity S, Szyper-Kravitz M, Shoenfeld Y (2009). "Transverse myelitis and vaccines: a multi-analysis". Lupus. 18 (13): 1198–204. doi:10.1177/0961203309345730. PMID 19880568.
  16. Giobbia M, Carniato A, Scotton PG, Marchiori GC, Vaglia A (1999). "Cytomegalovirus-associated transverse myelitis in a non-immunocompromised patient". Infection. 27 (3): 228–30. doi:10.1007/bf02561538. PMID 10378139.
  17. Tippett DS, Fishman PS, Panitch HS (1991). "Relapsing transverse myelitis". Neurology. 41 (5): 703–6. doi:10.1212/wnl.41.5.703. PMID 2027486.
  18. Pandit L, Rao S (1996). "Recurrent myelitis". J Neurol Neurosurg Psychiatry. 60 (3): 336–8. doi:10.1136/jnnp.60.3.336. PMC 1073861. PMID 8609515.
  19. Bashir K, Whitaker JN (2000). "Importance of paraclinical and CSF studies in the diagnosis of MS in patients presenting with partial cervical transverse myelopathy and negative cranial MRI". Mult Scler. 6 (5): 312–6. doi:10.1177/135245850000600503. PMID 11064439.
  20. Kaplin AI, Deshpande DM, Scott E, Krishnan C, Carmen JS, Shats I; et al. (2005). "IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis". J Clin Invest. 115 (10): 2731–41. doi:10.1172/JCI25141. PMC 1224298. PMID 16184194.
  21. Borchers AT, Gershwin ME (2012). "Transverse myelitis". Autoimmun Rev. 11 (3): 231–48. doi:10.1016/j.autrev.2011.05.018. PMID 21621005.
  22. Tristano AG (2009). "[Autoimmune diseases associated with transverse myelitis. Review]". Invest Clin. 50 (2): 251–70. PMID 19662820.
  23. Cobo Calvo A, Mañé Martínez MA, Alentorn-Palau A, Bruna Escuer J, Romero Pinel L, Martínez-Yélamos S (2013). "Idiopathic acute transverse myelitis: outcome and conversion to multiple sclerosis in a large series". BMC Neurol. 13: 135. doi:10.1186/1471-2377-13-135. PMC 3856522. PMID 24090445.
  24. Krishnan C, Kaplin AI, Pardo CA, Kerr DA, Keswani SC (2006). "Demyelinating disorders: update on transverse myelitis". Curr Neurol Neurosci Rep. 6 (3): 236–43. doi:10.1007/s11910-006-0011-1. PMID 16635433.
  25. Mirich DR, Kucharczyk W, Keller MA, Deck J (1991). "Subacute necrotizing myelopathy: MR imaging in four pathologically proved cases". AJNR Am J Neuroradiol. 12 (6): 1077–83. PMID 1763730.

Template:WH Template:WS